HomeIKT • NASDAQ
add
Inhibikase Therapeutics Inc
Previous close
$1.96
Day range
$2.01 - $2.17
Year range
$1.13 - $4.20
Market cap
160.58M USD
Avg Volume
136.35K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
MarketWatch
18 hours ago
S&P 500 needs to fall 40% before buying opportunity of a lifetime: strategist
1.67%
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 5.74M | 309.48% |
Net income | -12.13M | -190.40% |
Net profit margin | — | — |
Earnings per share | — | — |
EBITDA | -12.92M | -193.89% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 97.54M | 636.06% |
Total assets | 98.60M | 579.69% |
Total liabilities | 3.73M | 5.80% |
Total equity | 94.87M | — |
Shares outstanding | 74.34M | — |
Price to book | 1.43 | — |
Return on assets | -62.77% | — |
Return on capital | -68.29% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | -12.13M | -190.40% |
Cash from operations | -5.35M | -55.28% |
Cash from investing | -38.76M | -1,732.19% |
Cash from financing | 99.68M | 72,280.72% |
Net change in cash | 55.58M | 1,075.70% |
Free cash flow | -1.19M | 53.15% |
About
Founded
2008
Headquarters
Website
Employees
15
